BMRN in the 13F filings
Biomarin Pharmaceutical Inc · CUSIP 09061G101
- Quarter end
- 30 Jun 2024
- the date the book describes
- Filed
- 14 Nov 2024
- latest of these filings; the earliest 9 Aug 2024
- Managers listing it
- 16
- at least, of 95 tracked, among listed positions
- Comparable managers
- 94
- filed both Q1 2024 and Q2 2024; 13 listed it in both
- Shares listed
- 39,605,195
- combined, among listed positions
- Reported value
- $3.3bn
- combined, at the quarter end
Among the 94 comparable managers: 10 buyers (opened or added shares) and 6 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing BMRN in Q2 2024
16 of 16 holders
Largest increases and reductions, by shares
Increases
- Capital Research Global Investorsexisting position · 9,692,566 shares now+3,171,905
- Viking Global Investors LPexisting position · 7,063,564 shares now+647,276
- Neuberger Berman Group LLCexisting position · 1,094,193 shares now+628,463
- Holocene Advisors LPexisting position · 713,104 shares now+517,108
- Hudson Bay Capital Management LPexisting position · 244,700 shares now+134,800
Reductions
- Millennium Management LLCexisting position · 1,118,724 shares now-1,158,455
- Two Sigma Investments LPexisting position · 340,450 shares now-360,049
- Two Sigma Advisers LPexisting position · 231,914 shares now-313,100
- Dodge & Coxexisting position · 13,930,493 shares now-62,450
- Moore Capital Management LPexisting position · 250,000 shares now-10,000
New positions and exits
New (1)
- Winton Group Ltd$509k
Exited (1)
- Point72 Asset Management LPwas $118m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2013 | 14 | $2.3bn | n.a. | n.a. |
| Q3 2013 | 14 | $2.8bn | n.a. | n.a. |
| Q4 2013 | 11 | $2.5bn | n.a. | n.a. |
| Q1 2014 | 8 | $2.1bn | n.a. | n.a. |
| Q2 2014 | 9 | $1.9bn | n.a. | n.a. |
| Q3 2014 | 8 | $2.5bn | n.a. | n.a. |
| Q4 2014 | 12 | $3.3bn | n.a. | n.a. |
| Q1 2015 | 15 | $5.4bn | n.a. | n.a. |
| Q2 2015 | 14 | $6.3bn | n.a. | n.a. |
| Q3 2015 | 20 | $5.1bn | n.a. | n.a. |
| Q4 2015 | 14 | $4.8bn | n.a. | n.a. |
| Q1 2016 | 10 | $3.4bn | n.a. | n.a. |
| Q2 2016 | 11 | $2.7bn | n.a. | n.a. |
| Q3 2016 | 17 | $3.7bn | n.a. | n.a. |
| Q4 2016 | 13 | $3.0bn | n.a. | n.a. |
| Q1 2017 | 11 | $3.2bn | n.a. | n.a. |
| Q2 2017 | 14 | $3.2bn | n.a. | n.a. |
| Q3 2017 | 16 | $3.9bn | n.a. | n.a. |
| Q4 2017 | 16 | $3.8bn | n.a. | n.a. |
| Q1 2018 | 17 | $3.3bn | n.a. | n.a. |
| Q2 2018 | 14 | $3.6bn | n.a. | n.a. |
| Q3 2018 | 14 | $3.6bn | n.a. | n.a. |
| Q4 2018 | 13 | $3.0bn | n.a. | n.a. |
| Q1 2019 | 15 | $3.1bn | n.a. | n.a. |
| Q2 2019 | 19 | $3.0bn | n.a. | n.a. |
| Q3 2019 | 13 | $2.1bn | n.a. | n.a. |
| Q4 2019 | 15 | $3.0bn | n.a. | n.a. |
| Q1 2020 | 14 | $2.5bn | n.a. | n.a. |
| Q2 2020 | 11 | $3.6bn | n.a. | n.a. |
| Q3 2020 | 12 | $3.0bn | n.a. | n.a. |
| Q4 2020 | 12 | $3.7bn | n.a. | n.a. |
| Q1 2021 | 10 | $3.1bn | n.a. | n.a. |
| Q2 2021 | 11 | $3.4bn | n.a. | n.a. |
| Q3 2021 | 14 | $3.0bn | n.a. | n.a. |
| Q4 2021 | 14 | $3.4bn | n.a. | n.a. |
| Q1 2022 | 19 | $3.0bn | n.a. | n.a. |
| Q2 2022 | 21 | $2.9bn | n.a. | n.a. |
| Q3 2022 | 25 | $3.1bn | n.a. | n.a. |
| Q4 2022 | 26 | $4.0bn | n.a. | n.a. |
| Q1 2023 | 20 | $3.3bn | n.a. | n.a. |
| Q2 2023 | 18 | $2.9bn | n.a. | n.a. |
| Q3 2023 | 18 | $2.9bn | n.a. | n.a. |
| Q4 2023 | 22 | $4.1bn | 14 | 8 |
| Q1 2024 | 19 | $3.6bn | 16 | 4 |
| Q2 2024 | 16 | $3.3bn | 10 | 6 |
| Q3 2024 | 16 | $3.0bn | 9 | 8 |
| Q4 2024 | 14 | $3.0bn | 11 | 2 |
| Q1 2025 | 16 | $3.3bn | 12 | 3 |
| Q2 2025 | 16 | $2.5bn | 12 | 5 |
| Q3 2025 | 16 | $2.3bn | 10 | 5 |
| Q4 2025 | 21 | $2.4bn | 24 | 19 |
| Q1 2026 | 15 | $2.6bn | 14 | 26 |
| Q2 2026 | 12 | $2.2bn | 13 | 22 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
BMRN and LLY →BMRN and JNJ →BMRN and VRTX →Choose a stock to compare with BMRN →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own BMRN, latest filings →Back to the 13F Explorer →